Visit SeraCare at the AMP 2018 Annual Meeting & Expo
Join us in San Antonio for one of the most important molecular diagnostics events of the year.
Learn More Now: Free eBook Download
We’re hosting two fabulous corporate workshops in which we’ll discuss practical ways to ensure NGS-based liquid biopsy assay sensitivity and regulatory compliance, and how to implement best-in-class NGS QC programs to maximize assay uptime and meet current guidelines. Our scientific staff will be on-hand to present our latest data in the poster sessions. See details on both below.
Visit us at booth 1412 to learn about:
- Accelerating the clinical implementation of liquid biopsy assays
- How SeraCare is leading the way in harmonizing tumor mutational burden measurement and assay standardization
- Ensuring the ongoing quality of your entire NGS workflow with best-in-class NGS QC solutions
Fill out the form for a free download of our latest guide to NGS assay validation, written by Dr. Bob Daber, one of our expert speakers.
Complete this form for your free download:
CORPORATE WORKSHOP
Achieving Better ctDNA Assay Sensitivity – Laboratory Perspectives
Wednesday, October 31, 2018 - 1:00pm Room: 304AB
Non-invasive ctDNA testing of cancer patients for treatment decisions and monitoring is a major advance towards precision diagnostics. One of the greatest challenges for ctDNA assays is to achieve assay sensitivities required for clinical applications while preserving specificity and overall assay performance. At this session, two perspectives will be presented. Tony Godfrey, PhD, Boston University Medical Center, will discuss the highly sensitive SiMSen-Seq assay that is being optimized to achieve 0.05% variant allelic fractions and Bob Daber, PhD, Gnosity Consults, will discuss his experience optimizing highly sensitive ctDNA assays for routine use in clinical laboratories.
Featured Speakers
Tony Godfrey, PhD
Associate Chair, Surgical Research Boston University School of Medicine
Dr. Godfrey’s research is focused on cancer genetics and molecular pathology. Research projects use state-of-the-art genetic and genomic approaches to address clinical needs in the areas of cancer diagnosis, prognosis and therapy. The Godfrey lab works closely with translational research teams comprised of surgeons, pathologists and oncologists in order to develop new molecular approaches to cancer detection, staging and treatment.
Bob Daber, PhD
Founder Gnosity Consults
Dr. Daber is a board-certified clinical geneticist with expertise in genomics and bioinformatics who has spent much of his career building clinical NGS programs. He has built and managed multiple clinical genomics laboratories, most recently at BioReference where he was in charge of NGS operations and R&D for both that company and its genetic testing subsidiary, GeneDx.
CORPORATE WORKSHOP
How Can Labs Implement a Best-In-Class, Robust, and Compliant Next-Generation Sequencing QC Program?
Wednesday, October 31, 2018 - 4:00 Room: 302B
Clinical laboratories face many challenges adopting new technologies into clinical testing. One of the most critical is achieving CAP / CLIA regulatory compliance. Next-generation sequencing technology provides many challenges due to complex sample preparation, multi-step sequencing, and data analysis workflows. These challenges extend to the overall QC strategy. At this session, two scientific thought leaders in advanced molecular pathology - John Pfeifer, MD, Washington University School of Medicine and Greg Tsongalis, PhD, Dartmouth Hitchcock Medical Center - will discuss their experiences applying up-to-date quality control systems and standardization to NGS oncology assays in order to meet current guidelines and regulatory compliances.
Featured Speakers
John Pfeifer, MD
Vice Chair for Clinical Affairs; Dept. of Pathology Washington University School of Medicine
Dr. Pfeifer is board-certified in anatomic pathology and molecular genetic pathology. He has been a practicing surgical pathologist for over 20 years, and is responsible for managing the Department of Pathology’s high-volume, high-complexity Clinical Pathology, Anatomic Pathology, and Neuropathology Divisions. He has helped lead the development of Genomics and Pathology Services at Washington University in St. Louis, a CAP/CLIA certified environment designed around next-generation sequencing (NGS) analysis to support patient care, clinical trials, and translational research studies.
Greg Tsongalis, PhD
Dartmouth Hitchcock Medical Center Professor of Pathology, and Director, Clinical Genomics and Advanced Technology
Department of Pathology Geisel School of Medicine, Dartmouth College
Dr. Tsongalis is a leading investigator in molecular oncology and clinical genomics and is a past President of the Association of Molecular Pathology. Dr. Tsongalis’ research includes developing novel technologies and approaches for biomarker discovery and molecular pathology using NGS and other advanced technologies. Dr. Tsongalis’ clinical lab focuses on DNA and RNA testing for oncology, pharmacogenomics, and genetic disease testing.
Scientific Poster Presentations
Friday, November 2 ~ 2:30pm - 3:30pm
ST092 - Optimization Studies for the Development of Highly Multiplexed Reference Materials in FFPE Format for Solid Tumor Profiling
TT034 - New Technology to Generate Commutable and Comprehensive Circulating Tumor DNA (ctDNA) Reference Materials for Next Generation Sequencing (NGS)
Saturday, November 3 ~ 9:45am – 10:45am
ID045: Technology to Produce Non-infectious Recombinant Virus as Reference Materials for Unculturable or Highly Dangerous Viral Pathogens
ST087: Enabling Standardized Testing of Liquid Biopsy Assays Detecting EGFR Mutations Using Bespoke Reference Materials
TT033: Highly Stable and Commutable NIPS Reference Materials for Validation, Proficiency Testing and Quality Control
TT051: The Use of Native, Amplified and Synthetic ctDNA to Assess Variant Calls from Targeted NGS Panels